Skip to content

Application of 18F-PSMA-1007 PET/CT imaging in diagnosis and treatment of prostate cancer

Application of innovative molecular probe 18F-PSMA-1007 PET/CT imaging in accurate diagnosis and treatment of prostate cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059170
Enrollment
Unknown
Registered
2022-04-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostatic cancer

Interventions

Sponsors

The First Affiliated Hospital Of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1)PSA increased by > 4.0ng/ml; 2) images and results of conventional MRI (T1WI, T2WI, DWI) are required; 3) Blood PSA test results are required; 4) Ultrasound or MRI found suspicious prostate nodules, PSA at any level; 5) Nodules can be touched in prostate area by digital rectal examination, and PSA is at any level; 6) Patients who have been diagnosed with prostate cancer but have not been treated; 7) Qualified accompanying insiders participated in this research; 8) Agree to conduct PET research and agree to follow-up for at least three years; 9) Participate voluntarily and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with claustrophobia and inability to lie still. 2) Patients with mental disorders and unable to cooperate with the examination. 3) Patients with other kinds of tumors at the same time.

Design outcomes

Primary

MeasureTime frame
Standard uptake value maximum;

Contacts

Public ContactHan Xingmin
xmhan@zzu.edu.cn13838178090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026